ASX Penny Stocks To Watch In October 2026

As the Australian market prepares for a potentially positive start to the week, investor sentiment remains cautious due to fluctuating bond yields and geopolitical factors. In this climate, penny stocks—often representing smaller or newer companies—continue to offer unique growth opportunities despite being considered a niche investment area. When these stocks are supported by solid financial health, they can provide attractive prospects for investors seeking under-the-radar companies with long-term potential.

We're going to check out a few of the best picks from our screener tool.

CTI Logistics (ASX:CLX)

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: CTI Logistics Limited, along with its subsidiaries, provides transport and logistics services in Australia and has a market cap of A$237.84 million.

Operations: The company generates revenue primarily from its Transport segment, which accounts for A$259.26 million, and its Logistics segment, contributing A$135.07 million.

Market Cap: A$237.84M

CTI Logistics Limited, with a market cap of A$237.84 million, has shown robust financial performance despite being a penny stock. The company's revenue from its Transport and Logistics segments reached A$259.26 million and A$135.07 million respectively, contributing to an annual sales increase to A$357.13 million from the previous year's A$325.43 million. Earnings grew significantly by 68.9% year-over-year, reflecting strong operational efficiency with high-quality earnings and improved net profit margins at 6.7%. Although short-term assets do not cover liabilities, debt levels are satisfactory with interest payments well covered by EBIT (4.9x).

• Dive into the specifics of CTI Logistics here with our thorough balance sheet health report.
• Gain insights into CTI Logistics' future direction by reviewing our growth report.

Clarity Pharmaceuticals (ASX:CU6)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Clarity Pharmaceuticals Ltd is a clinical stage radiopharmaceutical company focused on the research and development of oncology products in Australia and the United States, with a market cap of A$779.74 million.

Operations: Clarity Pharmaceuticals generates revenue from its Radiopharmaceutical Development segment, totaling A$10.53 million.

Market Cap: A$779.74M

Clarity Pharmaceuticals, with a market cap of A$779.74 million, is navigating the complexities of clinical-stage development while maintaining no debt over the past five years. The company reported an increase in revenue to A$18.53 million for the year ended June 30, 2026, though it remains unprofitable with a net loss of A$107.24 million. Its SECuRE trial has shown promising results in prostate cancer treatment efficacy and safety, contributing to its potential growth prospects despite current financial challenges. Clarity's experienced board and management team support strategic initiatives as they continue expanding clinical trials in oncology products across Australia and the U.S.

• Take a closer look at Clarity Pharmaceuticals' potential here in our financial health report.
• Explore Clarity Pharmaceuticals' analyst forecasts in our growth report.

Qualitas (ASX:QAL)

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: Qualitas Limited is an alternative real estate investment manager focusing on risk-adjusted investments in real estate private credit and equity, with a market cap of A$662.92 million.

Operations: The company's revenue is derived from two main segments: Direct Lending, which generated A$0.04 million, and Funds Management, contributing A$14.63 million.

Market Cap: A$662.92M

Qualitas Limited, with a market cap of A$662.92 million, has demonstrated strong earnings growth, with a 24.9% increase over the past year surpassing its five-year average of 20.1%. Despite low Return on Equity at 10.5%, the company maintains stability with short-term assets exceeding liabilities and interest payments well-covered by EBIT. Revenue rose to A$129.56 million for the year ended June 30, 2026, while net income reached A$41.72 million, reflecting improved profit margins from last year. However, negative operating cash flow suggests caution regarding debt coverage despite having more cash than total debt and trading below estimated fair value by analysts.

• Jump into the full analysis health report here for a deeper understanding of Qualitas.
• Evaluate Qualitas' prospects by accessing our earnings growth report.

Make It Happen

• Click here to access our complete index of 399 ASX Penny Stocks.
• Searching for a Fresh Perspective? This technology could replace computers: discover the 24 stocks are working to make quantum computing a reality.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com